Methotrexate NEW
| Price | $54 | $142 |
| Package | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-15 |
Product Details
| Product Name: Methotrexate | CAS No.: 59-05-2 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2026/07/15 |
Product Introduction
Bioactivity
| Name | Methotrexate |
| Description | Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors. |
| Cell Research | Methotrexate (MTX) is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Each cell line is studied in growth inhibition experiments using 96-well microtiter plates. As antifols are schedule dependent, preliminary experiments are aimed at defining the longest duration of exposure that would allow for continuous logarithmic phase growth of cells without changing of the culture media while maintaining a linear relationship between SRB optical density and cell number. Twenty-four hours after cell plating, the cell lines are exposed to the antifol for 120 h (three replicates per experiment). To ensure that a complete sigmoidal survival-concentration curve could be observed, the following drug concentrations are studied: Methotrexate (0.002-5 μM), AMT (0.0001-1 μM), PXD (0.0003-10 μM), TLX (0.0002-0.5 μM). Experiments are repeated at least twice[1]. |
| In vitro | METHODS: Six pediatric leukemia and lymphoma cell lines, NALM-6, NALM-16, JURKAT, CEM, RAMOS, and NAMALWA, were treated with Methotrexate (0.002-5 μM) for 120 h, and the proliferation inhibitory activity of the cells was assayed using the SRB method. RESULTS: The median IC50 of Methotrexate against tumor cells was 78 nM, and the IC50 of the six tumor cells ranged from 33-133 nM. [1] METHODS: Human ovarian cancer cells SKOV-3 were treated with Methotrexate (15-50 μM) for 24 h. Apoptosis was detected using AO/EtBr probe. RESULTS: Methotrexate induced apoptosis in SKOV-3 cells. [2] |
| In vivo | METHODS: To test for chronic toxicity, Methotrexate (0.25-6 mg/kg) was administered intraperitoneally to C57BL/6, DBA/2, and C3H mice five times per week for 12-18 months. RESULTS: The 0.25-2 mg/kg dose was well tolerated with minimal cytostasis in lymphoid tissues, testis and skin. 3-6 mg/kg dose produced well-known acute to subacute hematopoietic and gastrointestinal injuries leading to early death. [3] METHODS: To examine the mode of action in different types of rheumatoid arthritis (RA) and multiple sclerosis (MS) models, Methotrexate (0.1-5 mg/kg) was injected intraperitoneally once a day for fourteen days into RA and MS models with different pathogenesis. RESULTS: Methotrexate showed strong ameliorative effects in classical RA models such as CIA and PIA as well as in MS and EAE models.Methotrexate acts only prior to and dependent on T-cell activation in T-cell activated diseases. [4] |
| Storage | Keep away from direct sunlight, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 70 mg/mL (154.04 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.3 mg/mL (18.26 mM), Suspension. |
| Keywords | WR-19039 | WR 19039 | synthesis | RNASynthesis | RNA Synthesis | rheumatoid | reductase | NCI-C-04671 | NCI-C 04671 | Methotrexate | lymphoblastic | leukemia | Inhibitor | inhibit | immunosuppressant | hDHFR(dihydrofolate reductase) | DNASynthesis | DNA/RNA Synthesis | DNA Synthesis | DNA | CL-14377 | CL 14377 | arthritis | Apoptosis | antineoplastic | Antifolate | ADCCytotoxin | ADC Payload | ADC Cytotoxin |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Metronidazole | Formamide | Thymidine | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP8Y
|
.GZ HONESTCHEM CO.,LTD
|
2026-07-25 | |
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-24 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-07-24 | ||
| $142.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-15 | |
| $50.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
| $10.50 |
VIP6Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1000.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | ||
| $150.00 |
Hebei Zhuanglai Chemical Trading Co Ltd
|
2025-05-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY